Bio-FD&C Co. Ltd. (251120) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Bio-FD&C Co. Ltd. KRW 19,229, price KRW 9,170, upside +109.7%, quality 73 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Bio-FD&C Co. Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
BIO-FD&C Co.,Ltd. develops active ingredients for anti-aging cosmetics in South Korea.
Show more
BIO-FD&C Co.,Ltd. develops active ingredients for anti-aging cosmetics in South Korea. It offers plant cell, peptide, natural extract, and biomolecule products for wrinkle improvement/skin regeneration, skin brightening, acne, skin irritation, wound healing, scalp improvement, skin moisturizing, fine dust, hair loss improvement, pores, lifting, whitening, skin texture, anti-inflammation/skin soothing, and anti-oxidation. The company was founded in 2005 and is headquartered in Incheon, South Korea.
Stock analysis
Bio-FD&C Co. Ltd. (251120) currently trades at 9,170 KRW, while our model-based Fair Value estimate is 19,229 KRW, implying the stock looks roughly 52.3% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 19,229 KRW per share, and 18 of the 24 models we run sit above the 9,170 KRW price.
Bear case: the Asset-Based group reads lowest at 5,483 KRW, and 6 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: 11,061 KRW (bear) to 24,998 KRW (bull), the price of 9,170 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 73/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Bio-FD&C Co. Ltd. reported revenue of 19.2B KRW in FY2025 versus 12.0B KRW in FY2021, a compound +12.5%/yr. Reported net income was 6.7B KRW in FY2025, compounding +23.1%/yr from FY2021.
Key figures
Market cap 78.2B KRW (≈ $57.5M) · P/S ratio 3.50 · Net margin 34.8% · Return on equity 9.1% · Return on assets (EBIT) 9.1% · Operating margin 25.7% · Revenue (TTM) 18.9B KRW · Revenue growth (YoY) −7.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 50% below its 52-week high and 29% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 110%, 251120 screens cheaper than that median.
Fair Value models
Bear 11,061 KRWFair Value 19,229 KRWBull 24,998 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.95/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+19.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.3%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.1%
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+16.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+16.9%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.34% → 33%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−16.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −18.1% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 650 stocks
Beats the industry median on 7/8 measures
Overall it ranks above its industry peers.
Valuation
Quality Score73 · Top 25%
Fair Value upside+110% · Top 25%
Profitability
Return on equity (TTM)9% · Top 25%
Return on assets5% · Top 25%
Net margin (TTM)33% · Top 25%
Operating margin (TTM)26% · Top 25%
Growth and dividend
Revenue growth−8% · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Bio-FD&C Co. Ltd. (251120) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 19,229 KRW versus a price of 9,170 KRW, about +110% upside (undervalued).
What is the fair value of 251120?
Our model-based fair value for Bio-FD&C Co. Ltd. is 19,229 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 9,170 KRW.
What is the quality score of 251120?
Bio-FD&C Co. Ltd. has a Quality Score of 73/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bio-FD&C Co. Ltd. (251120)?
Our model-based price target is the fair value of 19,229 KRW (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 11,061 KRW, optimistic scenario 24,998 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Bio-FD&C Co. Ltd. stock forecast for 2026?
Our models put fair value at 19,229 KRW, about +110% upside versus a price of 9,170 KRW (undervalued). Cautious scenario 11,061 KRW, optimistic scenario 24,998 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Bio-FD&C Co. Ltd. (251120)?
Bio-FD&C Co. Ltd. reported trailing-twelve-month revenue of about 18.9B KRW (latest available figure, as of Sep 24, 2026).
What growth is priced into Bio-FD&C Co. Ltd. (251120)?
For today's price to be fair in a discounted-cash-flow model, Bio-FD&C Co. Ltd. would have to grow free cash flow by -16.4 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +17.3 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 251120 use?
Our models discount Bio-FD&C Co. Ltd. at 8.9 %: a base by market capitalisation (nano), damped by beta 0.31, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Bio-FD&C Co. Ltd. that is -16.4 % per year a year over ten years, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has Bio-FD&C Co. Ltd. (251120) delivered so far?
Over the past 5 years revenue at Bio-FD&C Co. Ltd. grew +17.3 % a year. The price currently implies -16.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Bio-FD&C Co. Ltd. (251120) growing?
The median revenue growth in the sector is +1.8 % a year. That is the yardstick for the growth priced into Bio-FD&C Co. Ltd. (-16.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Bio-FD&C Co. Ltd. (251120)?
The free-cash-flow yield on the price is 7.97 %: that much free cash flow Bio-FD&C Co. Ltd. produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Bio-FD&C Co. Ltd. (251120)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bio-FD&C Co. Ltd. it is 19,229 KRW per share (as of Sep 24, 2026), against a price of 9,170 KRW. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Bio-FD&C Co. Ltd. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 251120 trades below its calculated fair value: price 9,170 KRW, fair value 19,229 KRW, a gap of about +110% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 251120?
No. The price is what the market pays today (9,170 KRW); the fair value is what the company's own numbers justify (19,229 KRW). For Bio-FD&C Co. Ltd. the two are 10,059 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Bio-FD&C Co. Ltd. worth?
The market values Bio-FD&C Co. Ltd. at about 78.2B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 9,170 KRW; our models calculate a fair value of 19,229 KRW per share.
What do the bullish and bearish scenarios say about 251120?
Our models span a range for Bio-FD&C Co. Ltd.: cautious scenario 11,061 KRW, base 19,229 KRW, optimistic 24,998 KRW per share (as of Sep 24, 2026, price 9,170 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Bio-FD&C Co. Ltd. (251120)?
Balance-sheet figures for Bio-FD&C Co. Ltd. (as of Sep 24, 2026): return on equity 9.1%. They feed the Quality Score of 73/100, which measures business quality independently of the share price.
How far is 251120 from its 52-week high?
Bio-FD&C Co. Ltd. trades at 9,170 KRW, about 50% below its 52-week high of 18,350 KRW and 29% above the low of 7,090 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 19,229 KRW is for.
Which stocks are comparable to Bio-FD&C Co. Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bio-FD&C Co. Ltd. stock attractive at the current price?
The data as of Sep 24, 2026: price 9,170 KRW, calculated fair value 19,229 KRW (+110%), Quality Score 73/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 251120 calculated?
We run Bio-FD&C Co. Ltd. through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 19,229 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Bio-FD&C Co. Ltd. currently trades 110 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bio-FD&C Co. Ltd. (251120)?
The closing price on Sep 23, 2026 was 9,170 KRW. Our model-based fair value is 19,229 KRW, about +110% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bio-FD&C Co. Ltd. right now?
The rarer combination: high quality (73/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (11,061 KRW). The market is more pessimistic than our downside scenario. A fairly wide model range (11,061 KRW to 24,998 KRW) leaves room in how you read the outcome.
Key figures of Bio-FD&C Co. Ltd.
How large is the market capitalisation of Bio-FD&C Co. Ltd. (251120)?
The market capitalisation of Bio-FD&C Co. Ltd. is 78.2B KRW (≈ $57.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bio-FD&C Co. Ltd. (251120)?
The price-to-sales ratio of Bio-FD&C Co. Ltd. is 3.50 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Bio-FD&C Co. Ltd. (251120)?
The net margin of Bio-FD&C Co. Ltd. is 34.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bio-FD&C Co. Ltd. (251120)?
The return on equity (ROE) of Bio-FD&C Co. Ltd. is 9.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bio-FD&C Co. Ltd. (251120)?
On an EBIT basis the return on assets of Bio-FD&C Co. Ltd. is 9.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bio-FD&C Co. Ltd. (251120)?
The operating margin of Bio-FD&C Co. Ltd. is 25.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bio-FD&C Co. Ltd. (251120)?
Revenue at Bio-FD&C Co. Ltd. is growing −7.5% versus a year earlier (3y avg +6.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Bio-FD&C Co. Ltd. (251120)?
Earnings per share at Bio-FD&C Co. Ltd. are growing −28.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Bio-FD&C Co. Ltd. (251120) carry?
The net debt of Bio-FD&C Co. Ltd. is 251M KRW (fiscal year 2020, ≈ 0.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Bio-FD&C Co. Ltd. in the live analysis
One click puts Bio-FD&C Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
